Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michelle Sitzman

Physician Assistant, Medical Lincoln, NE Physician Assistant

NPI 1568469419 CMS profile 3216320

7100 Stephanie Ln Ste 100, Lincoln, NE 68516

Open in the dashboard

General payments

$206,268

907 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michelle Sitzman of Lincoln, NE is reported in the CMS Open Payments database as having received $206,268 across 907 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $107,721 268
2024 General $52,673 225
2023 General $38,641 235
2022 General $5,660 103
2021 General $1,572 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Sitzman
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Michelle Sitzman were reported at $107,721. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Michelle Sitzman Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,572 $156 $41–$563 $132
2022 $5,660 $185 $55–$649 $149
2023 $38,641 $199 $58–$717 $160
2024 $52,673 $206 $62–$740 $164
2025 $107,721 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Arcutis Biotherapeutics, Inc. $52,980 100 payments
  2. Incyte Corporation $38,379 116 payments
  3. Regeneron Healthcare Solutions, Inc. $36,207 116 payments
  4. AbbVie, Inc. $28,642 169 payments
  5. Galderma Laboratories, L.P. $24,959 42 payments
  6. Genzyme Corporation $10,668 26 payments
  7. Organon LLC $5,239 13 payments
  8. Verrica Pharmaceuticals Inc. $1,889 4 payments
  9. Kowa Pharmaceuticals America, Inc. $1,681 3 payments
  10. UCB, Inc. $1,053 53 payments
  11. Other $4,570 265 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $117,206 97 payments
  2. Consulting Fee $35,413 25 payments
  3. Travel and Lodging $34,666 91 payments
  4. Food and Beverage $14,606 681 payments
  5. Honoraria $3,575 2 payments
  6. Education $802 11 payments
Products named General payments · program years 2021–2025
  1. Zoryve $41,212 71 payments
  2. OPZELURA $38,265 114 payments
  3. DUPIXENT Inflammation And Immunology $26,383 89 payments
  4. NEMLUVIO $24,569 29 payments
  5. RINVOQ $18,485 58 payments
  6. DUPIXENT Immunology $10,618 29 payments
  7. DUPIXENT Immunology And Inflammation $9,934 29 payments
  8. SKYRIZI Immunology $7,380 20 payments
  9. VTAMA $5,554 23 payments
  10. SKYRIZI Immunology $2,750 87 payments
  11. Other $11,375 452 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

703

Median for Physician Assistant: 241

Drug cost

$393,504

Median for Physician Assistant: $4,110

Branded share of claims

16.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 16 $114,492
Dupixent Pen Dupilumab Brand 29 $109,490
Taltz Autoinjector Ixekizumab Brand 12 $81,119
Dupixent Syringe Dupilumab Brand 16 $70,621
Doxycycline Ir-Dr Doxycycline Monohydrate Brand 11 $4,069
Metronidazole Generic 32 $2,119
Clobetasol Propionate Generic 51 $1,973
Imiquimod Generic 66 $1,903
Ketoconazole Generic 109 $1,570
Valacyclovir Valacyclovir Hcl Brand 29 $1,120

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$147,131

Of which drugs: $790

Medicare patients

1,122

Average age 74

Services billed

6,719

723 women, 399 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 45%
Chronic kidney disease 21%
Ischemic heart disease 20%
Osteoporosis 18%
Diabetes 17%
Cancer 15%
Depression 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 22 84 $53

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OPZELURA
$19,880 — —
Zoryve
$10,135 — —
DUPIXENT
$9,258 45 —
RINVOQ
$7,994 — —
SKYRIZI
$2,173 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

907 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record